Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial.
Mansfield AS, Wei Z, Mehra R, Shaw AT, Lieu CH, Forde PM, Drilon AE, Mitchell EP, Wright JJ, Takebe N, Sharon E, Hovelson D, Tomlins S, Zeng J, Poorman K, Malik N, Gray RJ, Li S, McShane LM, Rubinstein LV, Patton D, Williams PM, Hamilton SR, Conley BA, Arteaga CL, Harris LN, O'Dwyer PJ, Chen AP, Flaherty KT.
Mansfield AS, et al.
NPJ Precis Oncol. 2022 Mar 1;6(1):13. doi: 10.1038/s41698-022-00256-w.
NPJ Precis Oncol. 2022.
PMID: 35233056
Free PMC article.